Want to see SANA full AI Analyst Report?
Top Page
Sana Biotechnology
(NASDAQ:SANA)
Select Model
Select Model
Rating:46Neutral
Price Target:
$3.00
▼(-26.83% Downside)
Action:Reiterated
Date:09/10/26
Overall score is held down primarily by weak financial performance (no revenue, large ongoing losses, and continued cash burn with declining equity), which is the highest-weighted factor. Technicals add pressure given the stock trading below major moving averages, despite oversold indicators suggesting potential near-term stabilization. Valuation contributes only modestly because a negative P/E and no dividend yield limit the usefulness of standard valuation support.
Positive Factors
Clinical Pipeline Validation
Durable clinical validation for UP421 provides evidence that Sana’s hypoimmune technology can preserve cell function without immunosuppression. Progress toward SC451’s IND and planned manufacturing and trial steps could convert the platform into a broader development pipeline over the next several quarters.
Negative Factors
No Demonstrated Revenue Engine
Sana has not demonstrated a recurring product-revenue base, leaving its business model dependent on research progress, collaboration economics, and future commercialization. Persistent net losses mean pipeline programs must create meaningful clinical and commercial value before the company can establish durable operating earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical Pipeline Validation
Durable clinical validation for UP421 provides evidence that Sana’s hypoimmune technology can preserve cell function without immunosuppression. Progress toward SC451’s IND and planned manufacturing and trial steps could convert the platform into a broader development pipeline over the next several quarters.
Read all positive factors
Sana Biotechnology (SANA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.03B
Dividend YieldN/A
Average Volume (3M)2.49M
Price to Earnings (P/E)―
Beta (1Y)1.44
Revenue GrowthN/A
EPS Growth28.46%
CountryUS
Employees142
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.76
Shares Outstanding299,360,630
10 Day Avg. Volume2,102,960
30 Day Avg. Volume2,487,055
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)6.41
Price to Sales (P/S)0.00
P/FCF Ratio-7.12
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.00Price Target Upside95.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.67
Revenue Forecast (FY)N/A
Sana Biotechnology Business Overview & Revenue Model
Company Description
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical ne...
How the Company Makes Money
As of the most recently available public disclosures, Sana Biotechnology has not reported a recurring product-revenue base from marketed therapies; its business model has primarily been to fund R&D through cash on hand and external financing, and ...
Sana Biotechnology Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.39M | -12.75M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -200.99M | -231.42M | -249.37M | -258.70M | -253.85M | -344.86M |
| Net Income | -211.82M | -244.17M | -266.76M | -283.25M | -269.48M | -355.93M |
Balance Sheet | ||||||
| Total Assets | 431.52M | 416.89M | 501.02M | 565.30M | 822.72M | 1.13B |
| Cash, Cash Equivalents and Short-Term Investments | 160.49M | 138.38M | 152.50M | 205.19M | 423.96M | 551.00M |
| Total Debt | 73.74M | 78.86M | 94.20M | 104.10M | 108.25M | 110.94M |
| Total Liabilities | 276.95M | 256.01M | 250.52M | 277.79M | 323.40M | 400.90M |
| Stockholders Equity | 154.57M | 160.88M | 250.50M | 287.51M | 499.31M | 728.50M |
Cash Flow | ||||||
| Free Cash Flow | -135.06M | -144.77M | -256.58M | -273.61M | -310.93M | -280.92M |
| Operating Cash Flow | -132.24M | -143.83M | -223.15M | -253.58M | -290.05M | -251.05M |
| Investing Cash Flow | -102.60M | -40.24M | 17.45M | 172.01M | 210.56M | -245.80M |
| Financing Cash Flow | 220.64M | 128.73M | 199.75M | 31.65M | 4.91M | 631.75M |
Sana Biotechnology Technical Analysis
Negative
4.10
Price Trends
3.61
Negative
3.41
Negative
3.70
Negative
Market Momentum
0.01
Positive
36.23
Neutral
11.31
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SANA, the sentiment is Negative. The current price of 4.1 is above the 20-day moving average (MA) of 3.80, above the 50-day MA of 3.61, and above the 200-day MA of 3.70, indicating a bearish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 36.23 is Neutral, neither overbought nor oversold. The STOCH value of 11.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SANA.
Sana Biotechnology Risk Analysis
Sana Biotechnology disclosed 82 risk factors in its most recent earnings report. Sana Biotechnology reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sana Biotechnology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $1.79B | -12.64 | -56.19% | ― | -32.27% | -21.09% | |
56 Neutral | $970.13M | -14.04 | -30.31% | ― | 24.39% | 21.06% | |
54 Neutral | $465.35M | -3.70 | -196.63% | ― | 20.83% | 73.89% | |
54 Neutral | $5.30B | -11.23 | -24.39% | ― | -64.80% | 12.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $1.03B | -4.17 | -134.49% | ― | ― | 28.46% | |
44 Neutral | $645.70M | -3.15 | -188.27% | 6.80% | -17.90% | 32.10% |
* Healthcare Sector Average
SANA
Sana Biotechnology
3.17
0.26
8.93%
GERN
Geron
1.40
0.11
8.53%
EDIT
Editas Medicine
2.77
0.21
8.20%
CRSP
Crispr Therapeutics AG
53.45
1.64
3.17%
TSHA
Taysha Gene Therapies
5.34
2.09
64.31%
PRME
Prime Medicine, Inc.
3.47
-0.42
-10.80%
Sana Biotechnology Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Sana Biotechnology Highlights Progress in Diabetes and Oncology Therapies
Positive
Sep 8, 2026
On September 8, 2026, Sana Biotechnology released an updated corporate presentation for use at investor conferences, outlining recent progress in its pipeline and providing additional data on its hypoimmune cell technologies. The presentation unde...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.